SuperworthRegeneron Pharmaceuticals EPS REGN
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $40.44
- Latest quarter, Q2 FY26
- $12.23
- −5% on a year earlier
- Fiscal year 2025
- $41.54
- +8% on the year before
Regeneron Pharmaceuticals' earnings per share was $40.44 over the twelve months to Jun 30, 2026, up 2% on a year earlier.
In its latest quarter, Q2 FY26, it was $12.23, down 5% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 6% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $41.54 | +8% |
| FY2024 | $38.30 | +10% |
| FY2023 | $34.76 | −9% |
| FY2022 | $38.23 | −47% |
| FY2021 | $72.05 | +135% |
| FY2020 | $30.67 | +66% |
| FY2019 | $18.46 | −13% |
| FY2018 | $21.30 | +106% |
| FY2017 | $10.32 | +33% |
| FY2016 | $7.74 | +40% |
| FY2015 | $5.51 | +85% |
| FY2014 | $2.98 | −22% |
| FY2013 | $3.80 | −43% |
| FY2012 | $6.61 | n/a |
| FY2011 | −$2.44 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $12.23 | −5% | $40.44 | |
| Q1 FY26 | $6.75 | −7% | $41.02 | |
| Q4 FY25 | $7.84 | −3% | $41.54 | |
| Q3 FY25 | $13.62 | +18% | $41.78 | |
| Q2 FY25 | $12.81 | +3% | $39.70 | |
| Q1 FY25 | $7.27 | +16% | $39.30 | |
| Q4 FY24 | $8.08 | −21% | $38.30 | |
| Q3 FY24 | $11.54 | +30% | $40.42 | |
| Q2 FY24 | $12.41 | +46% | $37.77 | |
| Q1 FY24 | $6.27 | −13% | $33.86 | |
| Q4 FY23 | $10.20 | −3% | $34.76 | |
| Q3 FY23 | $8.89 | −24% | $35.05 |
Against its peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| VRTXVertex Pharmaceuticals | $17.18 | +23% a year |
| ONCBeOne Medicines | $0.43 | |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| INCYIncyte | $7.85 | +78% a year |
| EXELExelixis | $3.18 | +53% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| Peer median | $4.64 |
Where Regeneron Pharmaceuticals ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Regeneron Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.